多西他赛联合奈达铂治疗卵巢上皮性癌的疗效分析  

Study on the efficacy of docetaxel and nedaplatin in treatment of epithelial ovarian cancer

作　　者：杨琳[1] 孙慧超[2] 

机构地区：[1]四川省什邡市人民医院妇产科,四川什邡618400 [2]重庆医科大学附属儿童医院心血管内科,重庆400014

出　　处：《中国生化药物杂志》2014年第4期78-80,84,共3页Chinese Journal of Biochemical Pharmaceutics

基　　金：国家重点基础研究发展计划(973计划;2010CB529505)

摘　　要：目的观察多西他赛联合奈达铂(nedaplatin,NDP)方案对卵巢上皮性癌治疗的近期疗效和不良反应。方法选取2009年1月~2010年1月四川省什邡市人民医院收治的50例中晚期卵巢上皮性癌患者,随机分为治疗组和对照组,每组25例。治疗组采用多西他赛和奈达铂治疗,对照组给予卡铂。分析比较2组的近期疗效和不良反应。结果治疗组与对照组的近期总有效率分别为76.00%和52.00%,差异有统计学意义(P<0.05);治疗组白细胞减少发生率为36.00%,血小板减少发生率为24.00%,与对照组比较差异无统计学意义;治疗组恶心、呕吐、脱发反应发生率分别为12.00%、8.00%和44.00%,明显低于对照组(40%、28%和64%),2组比较差异有统计学意义(P<0.05);治疗组2年生存率为37.5%,对照组为28.00%,2组比较差异有统计学意义(P<0.05)。结论多西他赛联合奈达铂是治疗中晚期卵巢癌的有效化疗方案。Objective To observe the clinical efficacy of docetaxel and nedaplatin (NDP)in treatment of patients with epithelial ovarian cancer. Methods 50 cases with epithelial ovarian cancer collected in Shifang People’s Hospital from 2009 January to 2010 January were randomly divided into treatment group and control group,each had 25 cases.Treatment group were given docetaxel and nedaplatin,while control group were given carboplatin. The efficacy and adverse reactions in two groups were observed and compared.Results The recent efficacy in two groups were 76.00% and 52.00%, respectively,and the difference was significant (P <0.05 ).Compared with control group, the incidence of leucopenia was 36.00% and thrombocytopenia was 24.00% in treatment group,there was no significant difference between them.The incidences of nausea,vomiting and alopecia in treatment group were 12.00%,8.00% and 44.00%,which lower than that in control group (40%,28% and 64%),the differences between two groups were all significant(P<0.05 ).The two years survival rates in treatment group was 37.5%,and 28% in control group,there was no significant difference between two groups.Conclusion Docetaxel and nedaplatin has good clinical efficacy in treatment of epithelial ovarian cancer.

关 键 词：卵巢上皮性癌 多西他赛 奈达铂 

分 类 号：R730.5[医药卫生—肿瘤]